Understanding how kindlin-3 affects platelet function
Kindlin-3 signaling in platelets
['FUNDING_R01'] · VERSITI WISCONSIN, INC. · NIH-10761763
This study is looking at how a protein called kindlin-3 helps activate another protein in platelets that is important for blood clotting, with the goal of finding new ways to prevent dangerous blood clots, which could help patients with certain blood disorders.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | VERSITI WISCONSIN, INC. (nih funded) |
| Locations | 1 site (MILWAUKEE, UNITED STATES) |
| Trial ID | NIH-10761763 on ClinicalTrials.gov |
What this research studies
This research investigates the role of kindlin-3 in the activation of a specific protein in platelets called integrin αIIbβ3, which is crucial for blood clotting. By examining how kindlin-3 influences platelet behavior, the research aims to find ways to control excessive platelet accumulation that can lead to dangerous blood clots. The study involves analyzing the interactions between kindlin-3 and integrin proteins in platelets, which may help in developing new treatments for cardiovascular diseases. Patients with certain blood disorders may benefit from insights gained through this research.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals with cardiovascular disorders or conditions related to platelet dysfunction.
Not a fit: Patients with non-cardiovascular conditions or those without platelet-related issues may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that prevent dangerous blood clots in patients with cardiovascular diseases.
How similar studies have performed: Previous research has shown that targeting integrin activation can lead to significant advancements in treating blood clotting disorders, indicating a promising avenue for this investigation.
Where this research is happening
MILWAUKEE, UNITED STATES
- VERSITI WISCONSIN, INC. — MILWAUKEE, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: MA, YAN-QING — VERSITI WISCONSIN, INC.
- Study coordinator: MA, YAN-QING
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: cardiovascular disorder, Cardiovascular Diseases